These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10084418)

  • 21. [Pharmacological and pharmacokinetic properties of azithromycin (Zithromac), a novel 15-membered ring macrolide antibacterial agent].
    Matsunaga T
    Nihon Yakurigaku Zasshi; 2001 May; 117(5):343-9. PubMed ID: 11411344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.
    Kuti JL; Capitano B; Nicolau DP
    Pharmacoeconomics; 2002; 20(8):513-28. PubMed ID: 12109917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN; Yu VL
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
    Haggerty CL; Ness RB
    Clin Infect Dis; 2007 Apr; 44(7):953-60. PubMed ID: 17342647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
    Rahav G; Fidel J; Gibor Y; Shapiro M
    Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose azithromycin for respiratory tract infections.
    Law C; Amsden GW
    Ann Pharmacother; 2004 Mar; 38(3):433-9. PubMed ID: 14970367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.
    Vergis EN; Indorf A; File TM; Phillips J; Bates J; Tan J; Sarosi GA; Grayston JT; Summersgill J; YU VL
    Arch Intern Med; 2000 May; 160(9):1294-300. PubMed ID: 10809032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical evaluation of azithromycin for respiratory infectious diseases].
    Oizumi K
    Jpn J Antibiot; 2000 Jun; 53 Suppl B():72-81. PubMed ID: 12572090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azithromycin--review of key chemical, pharmacokinetic and microbiological features.
    Lode H; Borner K; Koeppe P; Schaberg T
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():1-8. PubMed ID: 8818841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia.
    Bohte R; van't Wout JW; Lobatto S; Blussé van Oud Alblas A; Boekhout M; Nauta EH; Hermans J; van den Broek PJ
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):182-7. PubMed ID: 7614957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical study on azithromycin in 10% fine granules and 100mg capsules in the field of pediatrics].
    Motohiro T; Nagai K; Yamada S; Tsumura N; Yamada T; Oda K; Sakata Y; Kato H; Gakuen Y; Imai S; Sasaki H; Morita J; Ikezawa S; Matsuo Y; Yamashita Y; Aramaki M; Araki H; Yasuoka C; Hayashi M; Ono E; Hashimoto N; Kubota K; Kawakami A; Toyoda A; Wada M
    Jpn J Antibiot; 1997 Mar; 50(3):272-97. PubMed ID: 9634360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia.
    Rizzato G; Montemurro L; Fraioli P; Montanari G; Fanti D; Pozzoli R; Magliano E
    Eur Respir J; 1995 Mar; 8(3):398-402. PubMed ID: 7789484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults.
    Drehobl MA; De Salvo MC; Lewis DE; Breen JD
    Chest; 2005 Oct; 128(4):2230-7. PubMed ID: 16236879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical evaluation of a new macrolide antibiotic, azithromycin, in the pediatric field].
    Meguro H; Terashima I
    Jpn J Antibiot; 1997 Mar; 50(3):265-71. PubMed ID: 9575355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
    Carbon C; Poole MD
    J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections.
    Powers JL
    Pediatr Infect Dis J; 1996 Sep; 15(9 Suppl):S30-7. PubMed ID: 8878244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical efficacy of oral clarithromycin monotherapy in patients with mild or moderate community-acquired pneumonia].
    Fujiki R; Rikimaru T; Aizawa H; Kawayama T
    Jpn J Antibiot; 2003 Dec; 56(6):712-8. PubMed ID: 15007880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.